The findings from the Cravatt lab reveal human proteins are better drug targets than previously thought.
The Davis lab study reveals possible strategy for treating memory disorders such as Alzheimer’s disease.
The new drug candidate from the Disney lab shows potential in treating spinocerebellar ataxia, a currently incurable disease.
The Wyatt lab’s HIV-like nanoparticles trigger a promising immune response.
The grant supports work in the Griffin and Kamenecka labs to develop novel compounds to enhance immunity in patients with cancer.